Researchers conducted a Phase 3 trial involving 589 adults who were hospitalized with COVID-19. The study compared patients receiving ensitrelvir along with standard care against those receiving a placebo and standard care to see if the medication improved recovery times.
The results showed no significant difference in clinical recovery between the two groups over a 60-day period. While the group taking ensitrelvir had lower levels of viral antigens in their blood by day five, this did not translate into faster overall recovery for the patients.
Safety data showed some differences, including a higher rate of hemorrhagic events in the ensitrelvir group compared to the placebo group. Because of factors like the milder nature of current variants and the high use of other treatments like remdesivir, these results may not apply to all situations. Patients should talk to their doctors about the best treatment options for COVID-19.
Common questions
Does ensitrelvir help patients recover faster from COVID-19?
The study found no significant difference in clinical recovery between patients who received ensitrelvir and those who received a placebo. While the medication was linked to lower viral antigens in plasma by day five, it did not result in a faster overall recovery for hospitalized adults.
What were the safety concerns with using ensitrelvir?
The study reported some differences in safety outcomes. Specifically, there was a higher rate of hemorrhagic events in the group receiving ensitrelvir (3.4%) compared to the placebo group (0.3%). You should discuss these risks and your treatment plan with a healthcare provider.
Why might the results be different for some patients?
The study noted that illness severity was lower during the Omicron era compared to earlier periods. Additionally, many patients in the trial were already receiving other treatments like remdesivir and corticosteroids, which may influence how medications work.
